A Prospective Observational Study to Assess the Efficacy & Safety of Sodium-glucose Cotransporter-2(SGLT2) Inhibitors as an Add-On drug to other Oral Hypoglycemic Agents in Reducing Glycated Hemoglobin and Weight in Type 2 Diabetes Mellitus at a Tertiary Care Hospital in Jaipur. - SWAG

开始日期2023-07-01

申办/合作机构-

JPRN-UMIN000055056

/ CompletedN/AIIT

Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes of Catheter Ablation for Atrial Fibrillation in Heart Failure Patients without Type-2 Diabetes. - NODACH-SGLT2 Study

开始日期2022-06-01

申办/合作机构

Fujita Health University

TCTR20210315003

/ Completed临床1/2期IIT

Effects of sodium glucose co-transporter-2 inhibitor on atrial arrhythmia burden in patient with cardiovascular implantable electronic device: a randomized controlled trial

开始日期2021-03-16

申办/合作机构-

100 项与 CPL-200-075 相关的临床结果

登录后查看更多信息

100 项与 CPL-200-075 相关的转化医学

登录后查看更多信息

100 项与 CPL-200-075 相关的专利（医药）

登录后查看更多信息

2,826

项与 CPL-200-075 相关的文献（医药）

2026-04-01·TISSUE & CELL

Empagliflozin as a potential therapy for PCOS: Restoring hormonal balance and ovarian function in a letrozole-induced rat model

Article

作者: Awad, Eman M ; Anter, Aliaa F ; Habib, Heba A ; Asiri, Yahya I ; Alqahtani, Saud ; El-Daly, Mahmoud ; Ahmed, Al-Shaimaa F ; Abdel Hafez, Sara Mn

BACKGROUND:

Polycystic ovarian syndrome (PCOS) is a prevalent endocrine disorder that often leads to infertility. The characteristic hyperandrogenemia and elevated luteinizing hormone /follicle stimulating hormone ratio, resulting in ovulation failure, are the hallmarks of PCOS. Recent preclinical and clinical studies revealed the potential of empagliflozin (EMPA; a sodium-glucose cotransporter-2 inhibitor) to improve PCOS symptoms. However, the effects of EMPA on endocrine disturbances and ovarian cyst formation were not thoroughly investigated.

OBJECTIVES:

The primary objective of this study was to explore the potential of EMPA as a treatment for PCOS.

METHODS:

PCOS was induced by daily administration of letrozole (1 mg/kg for 21 days). The PCOS group was then divided into PCOS (untreated), PCOS+EMPA (10 mg/kg), and PCOS + metformin (300 mg/kg). All groups, except for the vehicle-treated group, continued to receive letrozole throughout the 21-day treatment period. Serum and ovaries were collected for various measurements at the end of the experiments.

RESULTS:

The results of the study showed that induction of PCOS resulted in high testosterone levels, luteinizing hormone /follicle stimulating hormone ratio, and ovarian weights. Disturbed apoptosis and high transforming growth factor-β and inducible nitric oxide synthase expression were also evident in the PCOS group. EMPA treatment resulted in an ameliorative effect of these changes, comparable to metformin's effect.

CONCLUSION:

Our results suggest that EMPA could be a promising treatment for PCOS in rats, with its protective effect potentially mediated through its ability to restore hormonal imbalance and to restore transforming growth factor-β and inducible nitric oxide synthase expression, providing reassurance to the audience about its efficacy.

2026-03-01·BIOCHEMICAL PHARMACOLOGY

Common and distinct effects of sodium–glucose cotransporter-2 inhibitors on in vitro platelet activation

Article

作者: Taesakul, Supavit ; Khaeduang, Rasika ; Morales, Noppawan Phumala ; Wichaiyo, Surasak

Recent studies have demonstrated antiplatelet activity of sodium-glucose cotransporter-2 (SGLT2) inhibitors, particularly at high micromolar concentrations (10-30 µM). However, the effects of clinically relevant nanomolar concentrations on platelet function have not been reported. This study investigated the roles of empagliflozin and dapagliflozin, primarily at 0.625 µM, on platelet functions. In vitro assays were performed to assess platelet activation and aggregation in the presence of SGLT2 inhibitors using human platelet-rich plasma (PRP). The results demonstrated that empagliflozin and dapagliflozin produced a modest but significant (approximately 20 %) inhibition of collagen-induced platelet aggregation. In response to adenosine diphosphate (ADP), SGLT2 inhibitors increased phosphorylation of vasodilator-stimulated phosphoprotein (VASP), which may contribute to platelet inhibition. However, dapagliflozin, but not empagliflozin, elevated tumor necrosis factor alpha (TNF-α) secretion from activated platelets and enhanced endothelial nitric oxide synthase (eNOS) expression following stimulation with ADP. Molecular docking suggested binding of both SGLT2 inhibitors to the catalytic subunit of protein kinase A, yet only empagliflozin directly enhanced PKA catalytic activity. The effects of cariporide, a selective sodium-hydrogen exchanger 1 (NHE-1) inhibitor, were contradictory to those of SGLT2 inhibitors, particularly on TNF-α secretion, suggesting that SGLT2 inhibitors might not target platelet NHE-1. In conclusion, this study highlights both shared and distinct effects of SGLT2 inhibitors on platelet function. Differences in PKA function, eNOS expression, and TNF-α secretion may underlie the divergent activities between empagliflozin and dapagliflozin in platelets. These findings may contribute to a better understanding of the cardiovascular benefits of SGLT2 inhibitors.

2026-02-01·BIOCHEMICAL PHARMACOLOGY

The sodium-glucose cotransporter-2 inhibitor canagliflozin alleviates endothelial dysfunction in a rat bypass model

Article

作者: Korkmaz-Icöz, Sevil ; Karck, Matthias ; Lian, Shuo ; Ma, Ming ; Kraft, Patricia ; Szabó, Gábor ; Sayour, Alex Ali ; Mayer, Tobias

Ischemia/reperfusion (IR) injury during coronary artery bypass grafting surgery has detrimental impacts on endothelial integrity and function. Studies have suggested that canagliflozin (CANA) mitigates the risk of cardiovascular events, independently of diabetes. We hypothesized that the supplementation and/or administration of CANA protects vascular grafts in a bypass model in non-diabetic Lewis rats. The aortic arches of control rats (n = 9) were harvested, aortic rings were prepared, then mounted in organ baths. In the IR and IR + CANA_suppl groups (n = 8/group), aortic arches were preserved in either saline or CANA-supplemented saline (5 µM) for 1 h at 4 °C before transplantation. In the IR + CANA_inject and IR + CANA_suppl+inject groups (n = 9/group), aortic arches were preserved in cold saline or CANA for 1 h and recipients received CANA (10 µg/kg, intravenous) 5 min prior to reperfusion. After 1 h of in vivo blood reperfusion, ex vivo vascular function was assessed and immunohistochemistry was performed. The decreased maximum relaxation (R_max) to acetylcholine in the IR group compared to controls (20 ± 3 % vs 83 ± 2 %, p < 0.05) was improved in both the IR + CANA_inject (36 ± 2 % vs. 20 ± 3 %, p < 0.05) and IR + CANA_suppl+inject (45 ± 3 % vs. 20 ± 3 %, p < 0.05) groups. Additionally, the IR + CANA_suppl+inject rings exhibited a further increased R_max to acetylcholine compared to both the IR + CANA_suppl (45 ± 3 % vs. 31 ± 2 %, p < 0.05) and IR + CANA_inject (45 ± 3 % vs. 36 ± 2 %, p < 0.05) groups. Increased DNA strand breaks in the IR group compared to controls were decreased in all CANA groups. The reduced immunoreactivity of CD-31 was ameliorated in the IR + CANA_inject and IR + CANA_suppl+inject groups. CANA alleviates endothelial dysfunction induced by IR injury in a rodent model of revascularization.

项与 CPL-200-075 相关的新闻（医药）

2026-01-06

·drugs

Risk for Foot Disease Modestly Lower With SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in T2DM

TUESDAY, Jan. 6, 2026 -- For adults with type 2 diabetes mellitus (T2DM), new users of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) have a modestly lower risk for foot disease compared with glucagon-like peptide-1 receptor agonist (GLP-1 RA) users, according to a study published online Jan. 6 in the Annals of Internal Medicine . Frederik P.B. Kristensen, M.D., Ph.D., from Aarhus University in Denmark, and colleagues compared the risks for foot disease in new users of SGLT-2is and GLP-1 RAs in a cohort study using target trial emulation. Using national health care registry data, adults with T2DM initiating SGLT-2i or GLP-1 RA treatment were identified from 2013 to 2023. The registry cohort included 53,769 and 30,380 new users of SGLT-2is and GLP-1 RAs, respectively. The researchers found that any foot disease occurred in 10.8 and 12.0 percent of SGLT-2i and GLP-1 RA users, respectively, during six years of follow-up, corresponding to a risk ratio of 0.90 in an intention-to-treat analysis. Differences were not apparent until after year 3, when 40 and 32 percent of SGLT-2i and GLP-1 RA users, respectively, had discontinued initial treatment. Lower risk for neuropathy drove the modest reduction in risk among SGLT-2i users (risk ratio, 0.78). Similar risks for peripheral artery disease, foot ulcers, amputations, and all-cause mortality were seen for users of SGLT-2is and GLP-1 RAs. "The absolute differences were small, and whether this difference reflects a causal effect of the initial medication used is uncertain," the authors write. Abstract/Full Text (subscription or payment may be required)

临床结果

2026-01-06

·drugs

VA/DoD Recommendations Updated for Primary Care Management of CKD

TUESDAY, Jan. 6, 2026 -- In a clinical practice guideline (CPG) issued by the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) and published online Dec. 30 in the Annals of Internal Medicine , updated recommendations are presented for the primary care management of chronic kidney disease (CKD). Amy R. Schwartz, M.D., from the VA Connecticut Healthcare System in West Haven, and colleagues updated the 2019 VA/DoD CPG for primary care management of CKD. Twelve key questions were developed to guide the evidence review. The guidelines encompass 23 recommendations for the diagnosis, assessment, and monitoring of CKD; general management strategies; pharmacologic management of CKD and associated conditions; and contrast-associated acute kidney injury management. The guidelines include a strong recommendation for using urine albumin-to-creatinine ratio and estimated glomerular filtration rate for predicting CKD progression. Use of either an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) is strongly recommended to slow progression of CKD in patients with hypertension and albuminuria. In patients with CKD who have one or more of type 2 diabetes, albuminuria, or heart failure, sodium-glucose cotransporter 2 inhibitors are strongly recommended in addition to maximally tolerated ACE-Is or ARBs to reduce the risk for major adverse cardiovascular events (MACE), heart failure, progression of kidney disease, and mortality. To reduce CKD progression, MACE, and all-cause mortality, the addition of a glucagon-like peptide-1 receptor agonist to an ACE-I or ARB is strongly recommended in patients with type 2 diabetes and albuminuric CKD. "The VA/DoD CPG provides primary care clinicians with up-to-date practical recommendations for accurately staging CKD, predicting progression to kidney failure , and using pharmacotherapies to prevent progression to kidney failure and reduce the risk for MACE," the authors write. Abstract/Full Text

AHA会议

2025-12-04

·drugs

GLP-1 Receptor Agonist Use Linked to Chronic Cough Among Adults With Type 2 Diabetes

THURSDAY, Dec. 4, 2025 -- For patients with type 2 diabetes , there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and chronic cough , according to a study published online Nov. 26 in JAMA Otolaryngology-Head & Neck Surgery . Tyler J. Gallagher, M.D., M.P.H., from the Keck School of Medicine at the University of Southern California in Los Angeles, and colleagues examined the clinical association between GLP-1 RAs and chronic cough in a large multicenter cohort study using electronic medical record data from 70 health care organizations. Adults with type 2 diabetes and prescription of a GLP-1 RA were identified and compared to those prescribed another second-line diabetes medication (cohorts included 427,555 and 1,614,495 participants, respectively). The researchers found that individuals prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, dipeptidyl peptidase-4 (DPP-4) inhibitor, or sulfonylurea in a propensity score-matched analysis (adjusted hazard ratios, 1.12, 1.18, and 1.32, respectively). This finding was not seen compared with those prescribed a sodium-glucose cotransporter 2 (SGLT2) inhibitor. After removing patients with a previous diagnosis of gastroesophageal reflux, those prescribed GLP-1 RAs had a significantly increased risk for chronic cough compared with those prescribed any non-GLP-1 RA, DPP-4 inhibitor, SGLT2 inhibitor, or sulfonylurea (adjusted hazard ratios, 1.29, 1.36, 1.14, and 1.25, respectively). "This cohort study suggests that there is an association between GLP-1 receptor agonist use and new diagnosis of chronic cough," the authors write. "This association was present even among patients without a diagnosis of gastroesophageal reflux disease." Abstract/Full Text (subscription or payment may be required)